Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: swisstrader who wrote (52800)	3/9/2000 8:07:00 AM
From: swisstrader	Respond to of 122087

From RedHerring on SCLN: On page 420: Marcus Robins states: "Investors can find a number of small cap stocks on the verge of some very big things." He discusses: IART, SCLN, STAA, and NZYM. He compares the explosive growth of Celgene (CELG), with its 850% gain from $7 to $67, to these four stocks. Regarding SCLN he wrote: "How about seven quarters of 20 percent-plus sequential growth? SciClone Pharmaceuticals has Zadaxin, a new wonder drug with neglible side effects for treating Hepatitis B and C. Hepatitis can hide in the bloodstream for 20 years or longer, but it eventually leads to liver cancer or scarring of the liver. The World Health Organization estimates that nearly 350 million people worldwide are infected with Hepatitis B and 170 million suffer from Hepatitis C. Tests have shown that when added to the currently favored therapy for Hepatitis, Interferon, SciClone's lead drug candidate produced an encouraging positive response in 42 percent of the patients treated, compared with 17 percent of those treated with Interferon alone. The company estimates that potential Zadaxin revenues in Japan, Europe, and the US could reach $500 million. The firm should post positive earnings at the end of 2000."